<DOC>
	<DOC>NCT02942160</DOC>
	<brief_summary>A Phase 2, Open-Label Extension Study of EN3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy (commonly known as Cellulite).</brief_summary>
	<brief_title>EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)</brief_title>
	<detailed_description />
	<mesh_term>Edema</mesh_term>
	<criteria>Inclusion Criteria for Observation Phase: Voluntarily sign and date an informed consent agreement Have participated in and completed the doubleblind study EN3835201 Be willing to apply sunscreen to any treated quadrant before each exposure to sun Inclusion Criteria for Treatment Phase: Voluntarily sign and date an informed consent agreement Have participated in and completed the doubleblind study EN3835201 Be willing to apply sunscreen to any treated quadrant before each exposure to sun Have at least 1 quadrant with: a score of 3 or 4 (moderate or severe) as reported on the PCSS (Photonumeric Cellulite Severity Scale) by the subject or investigator, and a Hexsel CSS (Cellulite Severity Scale) score no greater than 13 Be judged to be in good health Have a negative urine pregnancy test at screening and be using an effective contraception method, be surgically sterile, or postmenopausal Exclusion Criteria for Observation Phase: Exclusion Criteria for Treatment Phase: Has used, or intends to use during the course of the study, other treatment of EFP on the legs or buttocks Is presently nursing a baby or providing breast milk for a baby Intends to become pregnant during the study Currently receiving, has received within 7 days before injection of study drug, or plans to receive an anticoagulant or antiplatelet medication History of stroke or bleeding</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>